116 related articles for article (PubMed ID: 2573101)
1. [Dopanergic agonists and schizophrenia].
Pidgeon JF; Wolf MA
Psychiatr J Univ Ott; 1989 Nov; 14(4):529-35. PubMed ID: 2573101
[TBL] [Abstract][Full Text] [Related]
2. Dopamine autoreceptor agonists in the treatment of schizophrenia and major depression.
Benkert O; Gründer G; Wetzel H
Pharmacopsychiatry; 1992 Nov; 25(6):254-60. PubMed ID: 1362997
[TBL] [Abstract][Full Text] [Related]
3. Partial brain dopamine D2 receptor agonists in the treatment of schizophrenia.
Coward D; Dixon K; Enz A; Shearman G; Urwyler S; White T; Karobath M
Psychopharmacol Bull; 1989; 25(3):393-7. PubMed ID: 2576320
[TBL] [Abstract][Full Text] [Related]
4. Increasing dopaminergic activity: effects of L-dopa and bromocriptine on human sensory gating.
Oranje B; Gispen-de Wied CC; Westenberg HG; Kemner C; Verbaten MN; Kahn RS
J Psychopharmacol; 2004 Sep; 18(3):388-94. PubMed ID: 15358983
[TBL] [Abstract][Full Text] [Related]
5. Dopamine receptors and the dopamine hypothesis of schizophrenia.
Seeman P
Synapse; 1987; 1(2):133-52. PubMed ID: 2905529
[TBL] [Abstract][Full Text] [Related]
6. [Schizophrenia and addiction: An evaluation of the self-medication hypothesis].
Potvin S; Stip E; Roy JY
Encephale; 2003; 29(3 Pt 1):193-203. PubMed ID: 12876543
[TBL] [Abstract][Full Text] [Related]
7. Novel pharmacological approaches to the treatment of schizophrenia.
Fink-Jensen A
Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
[TBL] [Abstract][Full Text] [Related]
8. A proposed mechanism for diurnal/nocturnal bruxism: hypersensitivity of presynaptic dopamine receptors in the frontal lobe.
Chen WH; Lu YC; Lui CC; Liu JS
J Clin Neurosci; 2005 Feb; 12(2):161-3. PubMed ID: 15749418
[TBL] [Abstract][Full Text] [Related]
9. Pathophysiology of schizophrenia and the role of newer antipsychotics.
Risch SC
Pharmacotherapy; 1996; 16(1 Pt 2):11-4. PubMed ID: 8778681
[TBL] [Abstract][Full Text] [Related]
10. Serotonergic modulation of dopamine neurotransmission: a mechanism for enhancing therapeutics in schizophrenia.
Haleem DJ
J Coll Physicians Surg Pak; 2006 Aug; 16(8):556-62. PubMed ID: 16899192
[TBL] [Abstract][Full Text] [Related]
11. New strategies with dopaminergic drugs: modified formulations of levodopa and novel agonists.
Goetz CG
Exp Neurol; 1997 Mar; 144(1):17-20. PubMed ID: 9126145
[TBL] [Abstract][Full Text] [Related]
12. [The involvement of 5-HT1a serotonin receptors in the pathophysiology and pharmacotherapy of schizophrenia].
Maćkowiak M; Czyrak A; Wedzony K
Psychiatr Pol; 2000; 34(4):607-21. PubMed ID: 11059260
[TBL] [Abstract][Full Text] [Related]
13. Dopamine autoreceptor agonists in the treatment of schizophrenic disorders.
Wetzel H; Benkert O
Prog Neuropsychopharmacol Biol Psychiatry; 1993 Jul; 17(4):525-40. PubMed ID: 8103233
[TBL] [Abstract][Full Text] [Related]
14. No effects of l-dopa and bromocriptine on psychophysiological parameters of human selective attention.
Oranje B; Gispen-de Wied CC; Westenberg HG; Kemner C; Verbaten MN; Kahn RS
J Psychopharmacol; 2006 Nov; 20(6):789-98. PubMed ID: 16478755
[TBL] [Abstract][Full Text] [Related]
15. From pharmacological profiles to clinical outcomes.
Kerwin R
Int Clin Psychopharmacol; 2000 Dec; 15 Suppl 4():S1-4. PubMed ID: 11252517
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine aspects in monitoring of dopaminergic drugs in man.
Hietala J; Koulu M; Scheinin M; Syvälahti E
Methods Find Exp Clin Pharmacol; 1985 Aug; 7(8):451-4. PubMed ID: 3935892
[TBL] [Abstract][Full Text] [Related]
17. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
[TBL] [Abstract][Full Text] [Related]
18. Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality.
Svensson TH
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1145-58. PubMed ID: 14642973
[TBL] [Abstract][Full Text] [Related]
19. Differential influence of D1 and D2 dopamine receptors on acute opiate withdrawal in guinea-pig isolated ileum.
Capasso A; Sorrentino L
Br J Pharmacol; 1997 Mar; 120(6):1001-6. PubMed ID: 9134209
[TBL] [Abstract][Full Text] [Related]
20. Bromocriptine in Parkinson disease.
Lieberman AN; Goldstein M
Pharmacol Rev; 1985 Jun; 37(2):217-27. PubMed ID: 3901046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
